Welcome to our dedicated page for ENvue Medical news (Ticker: FEED), a resource for investors and traders seeking the latest updates and insights on ENvue Medical stock.
ENvue Medical develops medical technology for enteral care, with a commercial focus on real-time guided bedside feeding tube placement. Its ENvue Navigation Platform is an FDA 510(k)-cleared electromagnetic navigation system for adult use that provides visual guidance as clinicians place feeding tubes into the gastrointestinal tract.
Company news commonly covers hospital adoption, group purchasing and distribution agreements, commercialization updates, and product-line expansion for ENFit syringes and enteral supplies. Updates also include intellectual-property activity tied to feeding tube navigation and the company's surface acoustic wave platform, including acoustic therapeutic technologies such as PainShield and UroShield for pain, bacterial colonization, and biofilm-related applications.
ENvue Medical (NASDAQ: FEED) entered a securities purchase agreement with an institutional investor for an equity line of credit (“ELOC”) providing up to $50 million in capital, forming an equity financing facility (the “Facility). The Facility is subject to specified terms, including receipt of stockholder approval.
According to ENvue, the Facility is intended to enhance financial flexibility, fund advancement of its next-generation medical technology platform, and support evaluation of selective strategic acquisitions and business development opportunities. The company’s near-term priorities include accelerating adoption of its ENvue feeding tube navigation system, expanding its installed hospital base, increasing recurring feeding tube revenue, advancing navigation, AI and automation technologies, improving operating efficiency and disciplined capital allocation, and evaluating accretive acquisitions that could broaden its product portfolio and market reach.
ENvue Medical (NASDAQ: FEED) has completed moving manufacturing of its NanoVibronix product line from Israel to the United States and consolidated its research and development operations in Tel Aviv, Israel. The company states these changes support its broader plan to reduce operating expenses and improve its cost structure.
According to ENvue Medical, domestic manufacturing is expected to enhance operational efficiency, reduce costs, streamline supply chain management, and improve operational oversight. The NanoVibronix line, including PainShield and UroShield, uses proprietary low-intensity surface acoustic wave technology for home or care settings.
ENvue Medical (NASDAQ: FEED) announced the deployment of an additional ENvue™ Navigation Platform at an existing major academic medical center in the Dallas-Fort Worth Metroplex. The hospital, which treats a high volume of hospitalized patients, is expanding use of the system as clinician adoption grows across care settings.
The ENvue platform delivers real-time bedside visualization for feeding tube placement using a minimally invasive electromagnetic navigation system that is FDA 510(k) cleared for adult use. According to ENvue Medical, strengthening its presence in the Dallas-Fort Worth healthcare market is an important element of its commercial strategy.
ENvue Medical (NASDAQ: FEED) appointed current director and internationally recognized health system leader Zeev Rotstein, M.D. as Chairman of the Board, succeeding David Johnson, who is leaving the board along with director Nino Pionati.
According to ENvue Medical, the company also added Zvi Joseph, Head of AI Governance, Risk & Compliance at Amdocs, and Lior Buchman, a finance executive who has executed more than $320 million in financings and M&A for venture-backed tech and medical device companies. The company highlights their combined clinical, AI governance and capital markets expertise as support for ENvue’s navigation and AI platforms.
ENvue Medical (NASDAQ:FEED) announced the first successful prototype demonstration of ENvue Drive, a robotic-assisted feeding tube automation tool built on its 510(k) FDA-cleared ENvue Navigation Platform.
The prototype integrates Ask Oscar AI navigation, real-time electromagnetic guidance, and robotic-assisted tube advancement for bedside enteral access under clinician supervision. ENvue Drive is an investigational prototype, not submitted to the FDA and not cleared or approved for clinical use.
ENvue Medical (NASDAQ: FEED) launched Ask Oscar, an AI-powered training platform for its ENvue Navigation feeding tube system. The tool lets clinicians train independently with real-time guidance and performance feedback, aiming to accelerate platform adoption and create scalable recurring revenue, while forming a foundation for future robotic-assisted ENvue Drive applications.
A peer-reviewed study of the ENvue Navigation Platform reported zero lung placements in 531 procedures, a 67% drop in ventilator-associated pneumonia, a 4,320% rise in post-pyloric feeding access, over 350 nursing hours saved annually and more than $1.5 million in annual cost avoidance in one health system.
ENvue Medical (NASDAQ: FEED) announced expansion of its ENvue Navigation Platform into an American Burn Association-verified burn intensive care unit within a major U.S. academic health network, marking a second deployment in the same system.
The bedside system helps clinicians place and confirm feeding tube position in real time and is currently deployed across 40 U.S. hospitals.
ENvue Medical (NASDAQ: FEED) reported an independent, peer-reviewed study from Inova Health System showing major safety and cost benefits from the ENvue Navigation Platform.
Across five hospitals and 531 placements, Inova saw a 67% drop in ventilator-associated pneumonia, no lung misplacements, 350+ nursing hours saved, 20% fewer X-rays, and an estimated $1.5 million in avoided costs in year one.
ENvue Medical (NASDAQ: FEED) will exhibit its ENvue™ Navigation Platform at the AACN NTI 2026 conference in Denver on May 21–22, 2026.
The FDA 510(k)-cleared electromagnetic system supports real-time guided bedside feeding tube placement and aligns with hospitals’ focus on workflow efficiency, nursing-led care, and patient safety.
ENvue Medical (NASDAQ: FEED) announced a three-year contract renewal with a leading integrated nonprofit health system operating 12 hospitals in Virginia and North Carolina. The ENvue Navigation Platform has been adopted as the standardized protocol for bedside enteral feeding tube placement across the entire network, embedding the technology into clinical workflow through 2028.
ENvue Medical plans to use this systemwide standardization as a model to pursue similar adoption across additional U.S. health systems.